The Reports and Insights, a leading market research company, has recently releases report titled “Remicade Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Remicade Biosimilar Market, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Remicade Biosimilar Market Overview
The global remicade biosimilar market was valued at US$ 2.0 Billion in 2024 and is expected to register a CAGR of 5.1% over the forecast period and reach US$ 3.1 Billion in 2033.
The Remicade biosimilar market is the market for biopharmaceuticals, medicines made of living cells; designed to replicate the reference drug infliximab (Remicade). This drug is used to treat certain autoimmune diseases, including rheumatoid arthritis, Crohn’s disease and ulcerative colitis. These are designed to have similar efficacy, safety, quality and lower price than Remicade allowing greater access to biological medicines.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2613
With patents on Remicade running out in several places, biosimilars have entered the market in a big way. Europe approved a number of biosimilars under the EMA, including Inflectra and Remsima. Due to healthcare cost reduction initiatives and acceptance of biosimilars among healthcare professionals, market is driving the growth. The take-up in the market is crucially impacted by hospital tenders and national reimbursement programs.
Remicade Biosimilar Market Growth Factors & Challenges
The high price of original biologics is the key component driving payers and providers towards biosimilars. Financial support and simplified rules help create biosimilars. Globally rising biologics used in management of autoimmune diseases has created a huge opportunity for biosimilar demand which includes infliximab.
Physicians and patients are reluctant to switch to the generic for reasons of efficacy or safety. Different rules and prices in different places will slow down the use of it uniformly. Also, the originator company may have a legal dispute and litigate patent registration delays. It is also difficult for new entrants due to complex manufacturing and quality assurance processes.
Key suggestions for the report:
- During the assessment period, the market segment for rheumatoid arthritis is anticipated to dominate the global Remicade biosimilar market owing to the chronic autoimmune disorder being highly prevalent and infliximab working effectively to manage it and improve patients’ quality of life.
- The adults will hold the largest revenue share because of increasing prevalence chronic conditions due to growing population along with remicade biosimilar are relatively cheaper than the original biologics.
- Hospital pharmacies are estimated to dominate the distribution channel segment, owing to the preference of healthcare professionals for administrating biologics in a controlled setting which ensures proper monitoring and management of adverse effects. Pharmacy of hospitals also has the capacity to store biologic drugs that have complex storage requirements.
- Europe is projected to be the dominant regional market in the global biosimilars pharmaceutics market owing to the strong healthcare infrastructure, supportive EMA regulations, and high acceptance of biosimilars in the region.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Remicade Biosimilar market share.
Key Trends in Remicade Biosimilar Industry
Recent trends include developing subcutaneous formulations of infliximab biosimilars for patient ease, augmenting marketing efforts to enhance confidence in biosimilar products, and the addition of biosimilars in NCDs. We see strategic partnerships forming between biosimilar developers and local distributors to increase access.
Remicade Biosimilar Market Key Applications & Industry Segments
The Remicade Biosimilar market is segmented by indication, age group, distribution channel and region.
By Indication
- Crohn’s Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
By Age Group
- Pediatric
- Adult
By Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
By Region
- North America (US and Canada)
- Latin America (Brazil, Mexico, Argentina, & Rest of LATM)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia, Poland, Benelux, Nordic, & Rest of Europe)
- Asia Pacific (China, Japan, India, South Korea, ASEAN, Australia & New Zealand, & Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, South Africa, United Arab Emirates, Israel, & Rest of MEA)
Leading Manufacturers in the Remicade Biosimilar Market
Some of the key manufacturers which are included in the Remicade Biosimilar market report are:
- Pfizer
- Merck
- Amgen
- Celltrion Healthcare
- Samsung Bioepis
- Sandoz
- Mylan
- Boehringer Ingelheim
- Baxter
- Biogen
- Sartorius AG
- Ranbaxy
- Among Others
Key Attributes
|
Report Attributes |
Details |
|
No. of Pages |
265 |
|
Market Forecast |
2025-2033 |
|
Market Value (USD) in 2024 |
2.0 billion |
|
Market Value (USD) in 2033 |
3.1 billion |
|
Compound Annual Growth Rate (%) |
5.1% |
|
Regions Covered |
Global |
View Full Report: https://www.reportsandinsights.com/report/remicade-biosimilar-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd.
1820 Avenue M, Brooklyn, NY, 11230, United States
Contact No: +1-(347)-748-1518
Email: sales@reportsandinsights.com
Website: https://www.reportsandinsights.com/
Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/
Follow us on twitter: https://twitter.com/ReportsandInsi1
